Literature DB >> 21331805

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.

Shinichiro Takahashi1, Taira Kinoshita, Masaru Konishi, Naoto Gotohda, Yuichiro Kato, Takahiro Kinoshita, Tatsushi Kobayashi, Syuichi Mitsunaga, Kohei Nakachi, Masafumi Ikeda.   

Abstract

BACKGROUND: Borderline resectable pancreatic cancer (BRPC) appears to be most frequently related to a positive surgical margin and has a poor prognosis after resection. However, few reports are available on differences in tumor characteristics and prognoses among resectable pancreatic cancer (PC), BRPC, and unresectable PC.
METHODS: Records of 133 patients resected for pancreatic ductal adenocarcinoma and 185 patients treated as locally advanced PC (LAPC) were reviewed.
RESULTS: Twenty-four patients who initially underwent resection (BRPC-s) and 10 patients who were initially treated as LAPC (BRPC-n) met the criteria for BRPC. Prognosis of BRPC was significantly better than that of unresectable PC, but was significantly worse than that of resectable PC. BRPC-s showed more frequent nerve plexus invasion (P < 0.01), portal vein invasion (P < 0.01), and loco-regional recurrence (P = 0.03) than resectable PC. The positive surgical margin rate was not significantly higher in BRPC-s (29%) than in resectable PC (19%) (P = 0.41).
CONCLUSIONS: BRPC had a poorer prognosis with more local failure than resectable PC although prognosis of BRPC was significantly better than that of unresectable PC. Considering the tumor and treatment characteristics, multidisciplinary treatment including resection is required for BRPC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21331805     DOI: 10.1007/s00534-011-0371-z

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  14 in total

1.  Surgery for Pancreatic and Periampullary Carcinoma.

Authors:  Abhishek Mitra; Ashwin D'Souza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2015-10-10       Impact factor: 0.656

2.  Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes.

Authors:  Sung Hwan Lee; Chang Moo Kang; Ho Kyoung Hwang; Sung Hoon Choi; Woo Jung Lee; Hoon Sang Chi
Journal:  Surg Endosc       Date:  2014-05-23       Impact factor: 4.584

Review 3.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

Review 4.  Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?

Authors:  Daniel M Halperin; Gauri R Varadhachary
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

Review 5.  Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: current status and future perspectives.

Authors:  Chang Moo Kang; Sung Hwan Lee; Woo Jung Lee
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Treatment of borderline resectable pancreatic cancer.

Authors:  Amanda B Cooper; Ching-Wei D Tzeng; Matthew H G Katz
Journal:  Curr Treat Options Oncol       Date:  2013-09

7.  National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival.

Authors:  Yoshiaki Murakami; Sohei Satoi; Masayuki Sho; Fuyuhiko Motoi; Ippei Matsumoto; Manabu Kawai; Goro Honda; Kenichiro Uemura; Hiroaki Yanagimoto; Makoto Shinzeki; Masanao Kurata; Shoichi Kinoshita; Hiroki Yamaue; Michiaki Unno
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

Review 8.  Selection criteria in resectable pancreatic cancer: a biological and morphological approach.

Authors:  Domenico Tamburrino; Stefano Partelli; Stefano Crippa; Alberto Manzoni; Angela Maurizi; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

10.  Validation of group B borderline resectable pancreatic cancer: retrospective analysis.

Authors:  Tak Geun Oh; Moon Jae Chung; Seungmin Bang; Seung Woo Park; Jae Bok Chung; Si Young Song; Jinsil Seong; Chang Moo Kang; Woo Jung Lee; Jeong Youp Park
Journal:  Gut Liver       Date:  2014-02-24       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.